Target intelligence / Profile preview

Undecaprenyl pyrophosphate and Lipid II intermediates (UPP/Lipid II)

Target
UPP/Lipid II
Molecular classification
Lipid, Isoprenoid, Peptidoglycan precursor
01

Overview

Bacterial peptidoglycan synthesis lipid pyrophosphate intermediates, most notably undecaprenyl pyrophosphate (C55-PP) and Lipid II, are essential molecules in the construction of the bacterial cell wall. These intermediates function as a lipid shuttle, where the C55-isoprenoid chain anchors hydrophilic cell wall building blocks and facilitates their transport across the hydrophobic cytoplasmic membrane (Müller et al., 2017). Once the building block is delivered to the growing peptidoglycan layer, the remaining undecaprenyl pyrophosphate must be dephosphorylated to undecaprenyl phosphate to be recycled for further rounds of transport (Stone & Strominger, 1971). Because these molecules are highly conserved across various bacterial species and are absent in mammalian cells, they represent ideal targets for antimicrobial therapy. Antibiotics such as vancomycin and teixobactin bind directly to Lipid II, effectively sequestering the precursor and preventing its incorporation into the cell wall, which leads to cell lysis and death (Ling et al., 2015). Other agents, like bacitracin, interfere with the recycling process by binding to the pyrophosphate group of C55-PP, thereby depleting the pool of available lipid carriers (Stone & Strominger, 1971). These targets are particularly valuable in the fight against multi-drug resistant pathogens, as the pyrophosphate and sugar moieties they contain are less prone to mutational changes compared to protein targets.

Other names
Bactoprenyl pyrophosphateUndecaprenyl diphosphateLipid ILipid IIC55-isoprenyl pyrophosphateC55-PP
02

Mechanism of action

Inhibition of peptidoglycan synthesis by sequestering lipid-linked precursors or preventing the recycling of the undecaprenyl phosphate carrier.

03

Biological functions

Peptidoglycan biosynthesisCell wall assemblyLipid carrier recyclingTransmembrane transport of precursors
04

Disease associations

Infection
05

Safety considerations

NephrotoxicityOtotoxicityInfusion-related reactions (Red Man Syndrome)Antibiotic resistance (e.g., VRE, VRSA)
06

Interacting drugs

Bacitracin

9 more in the full profile.

07

Biomarkers

Bacterial loadMinimum Inhibitory Concentration (MIC)Peptidoglycan synthesis rate

Beyond the preview

Go deeper on Undecaprenyl pyrophosphate and Lipid II intermediates (UPP/Lipid II).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Undecaprenyl pyrophosphate and Lipid II intermediates (UPP/Lipid II).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call